amifostine anhydrous has been researched along with Craniofacial Abnormalities in 1 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Craniofacial Abnormalities: Congenital structural deformities, malformations, or other abnormalities of the cranium and facial bones.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Forrest, CR | 1 |
| O'Donovan, DA | 1 |
| Yeung, I | 1 |
| Zeman, V | 1 |
| La Scala, G | 1 |
| Neligan, PC | 1 |
| Pang, CY | 1 |
1 other study available for amifostine anhydrous and Craniofacial Abnormalities
| Article | Year |
|---|---|
Efficacy of radioprotection in the prevention of radiation-induced craniofacial bone growth inhibition.
Topics: Amifostine; Animals; Bone Density; Craniofacial Abnormalities; Male; Orbit; Rabbits; Radiation Prote | 2002 |